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Lung cancer is a severe and aggressive disease affecting many individuals and 
families in Norway. Globally it is the most frequent cancer, both in number of new 
cases and in cancer deaths.  Life expectancy for patients with advanced lung cancer 
is short and the prognosis only slightly better today than two decades ago. The fact 
that most patients already have advanced or metastatic disease at diagnosis, is the 
main reason for the poor prognosis. Thus, for the majority of lung cancer patients the 
treatment aim is palliation of troublesome symptoms, better or consolidated health 
related quality of life (HRQOL) and prolongation of survival rather than cure. 
Accordingly, knowledge on how the disease and its treatment influence patients’ life 
and HRQOL is of utmost importance.   
 The VING study was a national multicenter study conducted by the Norwegian 
Lung Cancer Study Group. It was an open randomized phase III study of two third-
generation platinum-based chemotherapy combinations, both employed in the 
treatment of advanced non-small cell lung cancer (NSCLC), but previously not 
compared. The study was designed to find out whether one treatment was better 
than the other regarding survival and patients’ HRQOL. Other important tasks were to 
explore the toxicity profiles and to examine whether consequences from treatment 
side effects differed between the two treatment options.  
 From September 2003 to December 2004, 33 hospitals nationwide included 
444 patients into the VING study. Of these, 432 were eligible and constitute the study 
population. The combination of vinorelbine/carboplatin (VC) was compared with 
gemcitabine/carboplatin (GC). In both treatment arms, the patients received three 




quality of life questionnaires (QLQ) at study inclusion, before second and third 
chemotherapy course and then every eight week until nearly one year.  
 The first paper is the main study report and deals with the comparison of the 
two treatment arms with respect to survival, HRQOL and toxicity, according to the 
protocol. Later, the project evolved into new directions. After an inspiring lecture on 
treatment of lung cancer patients with compromised performance status given by Dr. 
Sculier at the Nordic Lung Cancer Meeting in Oulu, the idea for the second paper 
developed. A considerable proportion of lung cancer patients in general, have 
reduced general condition/performance status (PS) and whether these should 
receive combination chemotherapy is highly controversial. The second paper 
therefore compared patients with reduced PS (PS 2) to those with normal to slightly 
reduced PS (PS 0/1), within the VING-study. Finally, detailed analyses of HRQOL 
among the PS subgroups of patients are presented in the third paper.  
 A national phase III study accumulates huge amounts of information, provided 
by a large number of patients and local investigators. The given information was 
received, quality controlled and organized. All together, this represents a 
considerable piece of work reflecting patients’ experiences during advanced NSCLC 
treatment, summarized in this thesis.     
 
 






2.1 Lung Cancer in a global and national perspective.  
From being considered a rare disease at the beginning of the 20th century,1 lung 
cancer is now the most common cancer globally with estimated 965 446 new cases 
per year among males and 386 875 per year among women.2 It is an aggressive 
disease with poor prognosis which causes nearly 1.2 million deaths per year 
worldwide. This also makes it the leading cause of cancer related mortality.  
In Norway, 1369 men and 953 women were diagnosed with lung cancer in 
2006.3 Among Norwegian men, lung cancer is the second most frequent malignancy, 
following prostate cancer. The lung cancer incidence among men in Norway doubled 
during the last 40 years, but has leveled off through the last 10 -15 years. For 
women, lung cancer is the third most frequent cancer following breast cancer and 
colorectal cancer. The incidence of lung cancer among women has increased 6-fold 








Figure 1. Time trends in age-standardized rates in Norway for selected cancers. 
From: Cancer Registry of Norway. Cancer in Norway 2006 - Cancer incidence, 




Cigarette smoking is by far the most predominant cause of lung cancer. Tobacco is 
the single most preventable cause of death in the world today and will kill more than 
five million people this year, which is more than tuberculosis, HIV/AIDS and malaria 
combined.4 Cigarette smoke consists of a complex mix of more than 4000 different 
chemical compounds of which more than 60 are established carcinogens.5 Among 
these, polycyclic aromatic hydrocarbons, N-nitrosamines and aromatic amines are 
the strongest. Counting for about 90% of all cases, lung cancer would be a rather 
rare disease in the absence of cigarette smoking.  
In 2006, 24% of Norwegian adults were daily smokers.6 Strategies effectively 
preventing youths from starting smoking and promoting smoking cessation would 
thus be the most effective way to combat lung cancer.  
In addition, asbestos, radon and industrial/environmental compounds have 
also been proven causal for the development of lung cancer. Further, cigarette 
smoking appears to have an enhancing effect on these carcinogens.  
 
2.3 Histopathology 
Lung cancers arise from the respiratory epithelium (bronchi, bronchioles, and alveoli). 
Non-small cell lung cancer (NSCLC) is the most frequent sub-type of lung cancer and 
accounts for more than 80 % of the cases.  According to the new World Health 
Organization classification of lung tumors, the major histological subtypes are 
adenocarcinoma, squamous cell- and large cell carcinoma.7 Adenocarcinoma is the 
most common subtype in many countries and has increased by 10% in Europe 
during the last 20 years.7 Although all histological types of lung cancer have been 
connected to smoking, lung cancer can also occur in never smokers. The most  
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common sub-type of NSCLC seen in neversmokers, women, and young patients 
(<45 years) is adenocarcinoma.8 
 
2.4 Investigation, staging and prognosis 
Early lung cancers are often clinically silent, so presentation of symptoms often 
indicates more advanced disease. The most common initial symptom is cough, which 
is reported by 45-75% of patients.9 Lung cancer can be detected on chest x-rays 
based on patients’ symptoms or after routine chest investigations for other reasons. A 
suspicious lesion on chest x-ray normally requires a chest CT. Routine investigations 
of a chest mass include tissue biopsies to establish the diagnosis. Various 
techniques are available; bronchoscopy with brush samples or transtracheal needle 
aspiration with or without endoscopic ultrasound guidance, needle biopsy with or 
without CT-guidance or surgical techniques like mediastinoscopy, video assisted 
thoracoscopy or open chest surgery.  
After a confirmed diagnosis of NSCLC, staging procedures are necessary to 
establish the extent of disease and a basis for treatment decisions. A CT scan of the 
chest should include the upper abdomen to rule out liver metastasis or enlarged 
adrenal glands. MRI of the brain may be useful when large tumor burden or 
neurological symptoms are present, as lung cancer often spread to the brain. In case 
of bone pain or elevated calcium levels in the blood, a bone scan is valuable to rule 
out metastasis. A PET scan is helpful to rule out mediastinal and distant metastasis 
and to limit the gross volume target for radiation therapy.10,11 PET is today considered 
a routine investigation in most parts of the industrialized world.   
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NSCLC is staged according to the clinical stage classification from 1997:12 This 
classification is under revision and will be replaced by a revised version in 2009. 
 
Table 1. TNM staging of lung cancer 
Stage Tumor  Node  Metastasis Definition 
IA T1 N0 M0 T1: Tumor ≤3cm,  
without bronchosopic evidence of 
invasion proximal to the lobar 
bronchus. 
IB T2 N0 M0 T2: Tumor > 3 cm, or 
tumor of any size with one or more of 
the following characteristics: 
- infiltration of the visceral pleura 
- invades the main bronchus but > 2 
cm distal to the main carina 
- atelectasis or obstructive 
pneumonitis that extends to the hilus 
but does not involve the entire lung 
and without pleural effusion. 
IIA T1 N1 M0 N1: Metastasis to ipsilateral 
peribronchial and/or ipsilateral hilar 
lymph nodes, including direct invasion 






T3: Tumor of any size with invasion of 
the chest wall including adjacent 
rib(s), diaphragm, mediastinal pleura, 
parietal pericardium, or tumor in the 
main bronchus < 2 cm distal to the 
carina; or tumor associated with 
atelectasis or obstructive pneumonitis 













N2: Metastasis to ipsilateral 
mediastinal and/or subcarinal lymph 
nodes. 






N3: Metastasis to contralateral 
mediastinal, contralateral hilar, or 
ipsilateral and/or contralateral 
supraclavicular or scalene lymph 
nodes. 
IV Any T Any N M1 M1: Distant metastasis, including 
separate tumor nodules in a different 
lobe.  
 




The prognosis of lung cancer is generally poor. In Norway, the 5-year survival rates 
for lung cancers diagnosed between 1997 and 2001 were 10% for males and 13% 
for females.3 The 5-year survival from NSCLC according to disease stage is given in 
Figure 2. The results are presented by an International Staging Committee within the 
International Association for the Study of Lung Cancer and are based on a material 




Figure 2.  Overall survival, expressed as median survival time and 5-year survival, by 
clinical stage. As published in J. Thorac. Oncol13   
 
 
In advanced NSCLC, survival is strictly dependent on PS,14 and PS is the strongest 
prognostic factor for survival among these patients, followed by tumor size and 
weight loss.15 The ECOG PS classification16 is presented in Table 2. This is a five-
point scale worsening from 0 to 5, where PS ≥ 2 is characterized as poor 
performance. A significant share of the lung cancer patients has compromised 
performance status at the time of diagnosis. As many as 30 – 40% of advanced 
NSCLC patients are estimated to have PS 2.17,18 
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Table 2. ECOG performance status* 
Grade Definition 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all selfcare but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours 








Less than one third of NSCLC patients have local disease with possibilities of cure. 
For stages IA, IB, IIA, IIB and some IIIA patients, surgical resection is the treatment 
of choice followed by adjuvant chemotherapy to stage IIA – IIIA patients in good 
condition. Postoperative radiation is an option if surgery reveals N2 disease or at 
non-radical surgical margins. Medically inoperable patients can be treated with 
localized radiotherapy or combined chemoradiation.19  
The majority of newly diagnosed NSCLC patients present with locally 
advanced or metastatic disease.20 Patients with locally advanced disease should be 
offered chemoradiation if positive prognostic factors, i.e., tumor size < 7 cm, good 
performance status and no significant weight loss. For patients with poor prognostic 
factors or metastatic disease, the aim of the treatment is palliation of symptoms and 
prolongation of survival.  
Advanced NSCLC causes a wide range of distressing symptoms. Locally, the 
disease gives rise to dyspnea, cough, chest pain and hemoptysis while the systemic 
component causes fatigue and lack of appetite. Distant metastasis can cause 
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symptoms and pain from involved areas, and other complications. In addition, anxiety 
and depression is a considerable burden for these patients. According to Hopwood et 
al,21 the advanced NSCLC patient present with 14 symptoms on average. Due to 
long-term cigarette smoking and a high prevalence of respiratory and cardiovascular 
diseases, these patients often have massive co-morbidity,22 which adds to a more 
complex symptom picture, making treatment more toxic or not feasible at all.  
Both chemotherapy and palliative radiotherapy are valuable treatment options 
for stage IIIB and IV NSCLC. Already in 1948, dr. Karnofsky described favorable 
symptom relief among lung cancer patients administered nitrogen mustards.23 Still, 
the road to acceptance of chemotherapy as a valuable treatment possibility for 
advanced NSCLC has been long and characterized by nihilism.24 In 1995, the Non-
small Cell Lung Cancer Collaborative Group published “Chemotherapy in non-small 
cell lung cancer: a meta-analysis using updated data on individual patients from 52 
randomised clinical trials”, concluding on a 10% 1-year survival improvement by 
chemotherapy and best supportive care (BSC) vs. BSC alone.25 Since then, a large 
number of clinical studies have been published within this field, establishing the role 
of chemotherapy in advanced NSCLC. Still, in Norway the treatment of choice during 
the mid ‘90s continued to be radiotherapy. This was largely based on a randomized 
study comparing radiotherapy to chemotherapy in patients with inoperable NSCLC.26 
The study favored radiotherapy regarding response rates, toxicity and QOL.  
During the late nineties and the early years of this decade, third generation 
cytotoxic drugs like vinorelbine, gemcitabine, docetaxel and paclitaxel proved 
effective in advanced NSCLC both as single drugs and in combinations. Platinum-
based doublets including a third generation drug proved to be better than 
monotherapy, and equal in effect, but less toxic than three drug regimens. In 2004 
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these doublets were recommended as standard therapy.27 Which novel non-platinum 
agent to choose and the optimal treatment duration was debated.27 In 1997, an 
expert panel within the American Society of Clinical Oncology recommended a 
maximum of eight chemotherapy courses in patients with stage IV NSCLC.28  In the 
late 1990’s, the Norwegian Lung Cancer Study Group wanted to implement 
chemotherapy to advanced NSCLC patients in Norway. A randomized multicenter 
trial, the BLANK-study, was conducted in an attempt to establish the optimal duration 
of chemotherapy to patients with advanced NSCLC.29 Three vinorelbine/carboplatin 
(VC) courses were compared to 6 with respect to HRQOL and survival. There were 
no survival or HRQOL benefits for the longer regimen, consistent with data from two 
contemporary studies.30,31 The BLANK-study turned out to be an important 
contribution to establish shorter treatment regimens for advanced NSCLC. It also 
confirmed that VC was an appropriate treatment option for these patients at the 
doses chosen.   
Both cisplatin and carboplatin are used in the treatment of advanced 
NSCLC.32 Whether carboplatin may substitute cisplatin in 2-drug platinum-based 
combinations for advanced NSCLC, was investigated in a meta-analysis including 
abstracted data from 2945 patients.33 This meta-analysis failed to demonstrate an 
overall survival advantage for cisplatin-based as compared with carboplatin-based 
chemotherapy. On the other hand, it demonstrated a survival advantage of 11% in 
favor of cisplatin in a subset analysis of 2280 patients treated with novel agents in 
platinum combinations. The CISCA meta-analysis,34 an individual patient data meta-
analysis of 2968 advanced NSCLC patients, found cisplatin-based chemotherapy 
slightly superior to carboplatin-based chemotherapy with respect to response rate, 
but not overall survival. The authors conclude that cisplatin should remain the 
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reference platinum agent for treatment of the least advanced NSCLC patients with 
good prognosis, indicating that the less toxic and easier administered carboplatin 
could be preferred for more advanced disease and PS 2 patients.  
In the palliative setting, patients’ QOL, treatment toxicity and time hospitalized 
are considered more important issues. Thus, despite the indications that cisplatin 
gives a slightly better treatment outcome; carboplatin is a valuable alternative with a 
better toxicity profile, does not require hospitalization in contrast to cisplatin and is the 
drug of choice in palliative treatment of advanced NSCLC in Norway.  
Whether PS 2 patients should receive these new combination regimens is still 
controversial. Shorter life expectancy and expected enhanced treatment-related 
toxicity compared to PS 0/1 patients form the basis of this scepticism.27,35-39  The 
2003 ASCO Guidelines concluded that single-agent chemotherapy should be 
sufficient for NSCLC patients with PS 2.27 Nevertheless, PS 2 patients appear to 
have a survival benefit when treated with chemotherapy. Moreover, combination 
chemotherapy was associated with an improved 1-year survival when compared to 
single-agent therapy in advanced NSCLC PS 2 patients.40 Furthermore, in a meta-
analysis comparing the newer third generation agents with or without platinum-
compounds to best supportive care, individual data from 2714 patients revealed an 
increased 1-year survival in patients with PS ≥ 2 from 8% to 14%.41   
In the Norwegian Lung Cancer Study Group, BLANK was followed by the 
VING-study. Vinorelbine as monotherapy42,43 and in combination regimens37,42,44-47 
was considered highly promising. Also, the satisfying experience with the VC 
combination in the BLANK-study made VC the Norwegian standard regimen for 
advanced NSCLC. Hence, VC was used as the control arm in the VING-study. 
Meanwhile, gemcitabine had proved promising for advanced NSCLC both as 
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monotherapy48 and in platinum-based combinations.49-52 Gemcitabine/carboplatin 
(GC) was considered an interesting alternative as first line treatment. Based on the 
results from the BLANK-study, a randomized comparison between VC and GC would 
be based on three courses of chemotherapy.  
 
2.5.1 Carboplatin   
Carboplatin (cyclobutane-1,1-dicarboxylic acid) is a second generation platinum 
compound which act against cancer cells by binding to DNA and produce various 
cross-links which induces apoptosis.53 It has a different toxicity profile than cisplatin 
with less nephrotoxicity, ototoxicity and neurotoxicity.54 The dose limiting toxicity is, 
somewhat contrasting to cisplatin, bone marrow suppression.55 Carboplatin does not 
require hydration, which makes it convenient for outpatient administration. The major 
route of elimination is renal excretion. Calculation of carboplatin dosage by use of 
body surface area is considered insufficient.56 Instead, based on a patient's pre-
existing renal function, dosing is calculated according to the estimated area under the 
concentration versus time curve (AUC in mg/mLmin), either by the Chatelut57 or the 
Calvert58 formula.  
 
Chatelut’s formula 
Carboplatin dose (mg) = carboplatin clearance / AUC 
Carboplatin clearance (mL/min) = 0.134 x weight + [218 x weight x (1 - 0.00457 x 





Calvert’s formula   
Carboplatin dose (mg) = target AUC x (GFR + 25)  
GFR (mL/min) = 1.23 x (140 – age) x weight x sex / serum creatinine 
 
2.5.2 Vinorelbine 
Vinorelbine, or 3',4'-didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2,3-
dihydroxybutanedioate], is a semisynthetic vinca alkaloid derived from vinblastine. It 
inhibits cell growth by binding to the tubulin of the mitotic microtubules and blocks 
mitosis.59 Dose limiting toxicity is neutropenia.55,60   
  
2.5.3 Gemcitabine  
Gemcitabine, or dFdC (2'-deoxy-2',2'-difluorocytidine monohydrochloride), is a novel 
deoxycytidine analogue originally investigated for its antiviral effects, but since then 
developed as an anticancer therapy.61 It is grouped as a pyrimidine antagonist, an 
anti-metabolite which acts through inhibition of DNA-synthesis and repair in different 
ways.53 It is a lipophilic prodrug which in the intracellular environment is 
phosphorylated to active metabolites that incorporates into DNA and causes 
damage.55 Dose limiting toxicity is bone marrow suppression.  
Also, gemcitabine is a highly potent radio-sensitizer of human tumor cells.62 As 
a consequence, radiotherapy should be postponed until one week after gemcitabine 
treatment, and if radiotherapy is given, gemcitabine treatment should be awaited for 






2.6 Health Related Quality of Life – HRQOL 
Quality of life is a multidimensional term involving physical, psychological and social 
issues. It is used in many contexts, often without clarification of the exact meaning. 
The meaning is different for different people, depending on life situation and 
environment. Intuitively, QOL consists of satisfaction with life and a personal feeling 
of well-being. Satisfaction can be linked to cognitive aspects of QOL and happiness 
with emotional. One definition is the subjective experience concerning a persons 
life.63  WHO has defined QOL as a state of complete physical, mental and social well-
being, and not merely the absence of disease.  
QOL is difficult to define precisely and subjective of nature, which makes it 
difficult to measure. But despite these difficulties, it provides important information. A 
concern when introducing palliative cytotoxic treatment is whether benefits are 
overshadowed by toxicity and reduced QOL. Aspects of QOL that may be affected by 
disease and therapy have thus to be measured to comprehend the implications of 
offering a specific treatment and be able to compare different treatment alternatives. 
In this setting, the term health related QOL (HRQOL) is a better approach. HRQOL 
has been defined as the level of well being and satisfaction associated with an 
individual’s life and how it is affected by disease, accidents and treatment.64 
Measuring HRQOL also facilitates communication with patients regarding problems 
during different phases of the disease course. 
Back in 1948, the importance of HRQOL endpoints in palliative treatment was 
recognized, as Karnofsky published “The Use of the Nitrogen Mustards in the 
Palliative Treatment of Carcinoma With Particular Reference to Bronchogenic 




changes in PS and duration of improvement. During the last decades, HRQOL has 
become an increasingly important end-point in clinical studies, particular when the 
disease is beyond cure. A European experts panel argued in 2004 for HRQOL 
assessments in evaluating symptom relief and clinical benefit as endpoints in studies 
of PS 2 NSCLC patients.65 
Several instruments have been developed to measure HRQOL in diseases in  
general66-72 and in subgroups of lung cancer patients.73-75  Of these, the 
questionnaires developed by the European Organization for Research and Treatment 
of Cancer (EORTC) are widely used in malignant disease. 
The EORTC quality of life questionnaires (QLQ) are tools for assessing 
HRQOL of cancer patients participating in international clinical trials. The core 
questionnaire, the QLQ-C30 (Appendix 1),69 is a product of more than a decade of 
collaborative research. It was released in 1993, and has since then been frequently 
used in clinical cancer trials.  It includes five functional scales, three symptom scales, 
a global health status /QOL scale, and six single items as shown in Table 3. Global 
QOL, the functioning scales and some symptoms consists of more than one item, 
and the rest of the symptoms are single items.  
The lung cancer module (Appendix 2), LC-13, is constructed for use among a 
wide range of lung cancer patients.75 It covers both treatment side-effects like sore 
mouth, dysphagia, peripheral neuropathy and alopecia and symptoms of the disease 
like cough, hemoptysis, dyspnea and site specific pain. Dyspnea is assessed by a 
multi-item scale whereas the others are single items (Table 3). Both the QLQ-C30 
and the LC13 are validated and translated to Norwegian.  
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The patients answer the questionnaire by ticking off the preferred answer in graded 
boxes. These answers are scored according to the scoring manual from EORTC.76 
The scoring principle is the same in all cases: a raw score (RS) is estimated as the 
mean of the items contributing to the scale. Then, the RS is linearly transformed into 
scale scores ranging from 0 to 100: 
 
Scorefunctional scales  = (1 – (RS – 1)/range)100 
Scoresymptom scales/ global QOL  = ((RS – 1)/range)100 
 
Range is the difference between the maximum possible and the minimum possible 
value of RS. Most items are scored 1 to 4, giving range = 3, whereas global QOL 
are 7-point questions with range = 6. A high score represents a higher response 
level. Then, a high functional score/ global QOL represents high, or good, function/ 
global QOL whereas a high symptom score represents more severe symptoms.  
Missing data in HRQOL trials is a well known and described challenge.77 
Missing data in a series of measures provided by one patient, usually exclude that 
patient, and thus important information, from the summary analysis. A solution to this 
problem is to impute the missing data, which can be done in different ways.78 The 
advantage is keeping a patient with missing data, and thus the information provided, 
within the statistical analyses. Including data not given explicit by the patient into the 
analyses intuitively feels wrong. On the other hand, not imputing missing data is to 
assume that data from the patients without missing data are representative for the 
patients whom, for some reason, were missing.  Either way, missing data are related 
to difficulties analyzing and interpreting HRQOL data, and should thus be avoided if 
possible. 
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Table 3. Content of the EORTC core questionnaire version 3.0 and the lung cancer 
module LC-13. 
 
   No. of items Question no. 
QLQ-C30   
 Global Health Status/QOL   
  Global QOL 2 29,30 
 Functional scales   
  Physical function 5 1-5 
  Role function 2 6,7 
  Emotional function 4 21-24 
  Cognitive function 2 20,25 
  Social function 2 26,27 
 Symptom scales   
  Fatigue 3 10,12,18 
  Nausea and vomiting 2 14,15 
  Pain 2 9,19 
  Dyspnea 1 8 
  Insomnia 1 11 
  Appetite loss 1 13 
  Constipation 1 16 
  Diarrhea 1 17 
  Financial difficulties 1 28 
QLQ-LC13   
 Symptom scales   
  Dyspnea 3 3,4,5 
  Coughing 1 1 
  Hemoptysis 1 2 
  Sore mouth 1 6 
  Dysphagia 1 7 
  Peripheral neuropathy 1 8 
  Alopecia 1 9 
  Pain in chest 1 10 
  Pain in arm or shoulder 1 11 




3. Aims of the thesis 
 
The present thesis aimed to investigate outcome in patients with advanced non-small 
cell lung cancer receiving two different modern chemotherapy regimens within a 
national phase III study. 
 
More specified the aims were: 
 
VC vs. GC: 
• Examine whether there was any survival difference between patients treated 
with the two chemotherapy combinations  
• Examine whether there was any HRQOL differences during and after 
chemotherapy between the treatment arms, as measured by the EORTC 
QLQ-C30 and QLQ-LC13 
• Examine possible differences between the treatment arms with respect to 
hematological toxicity, and needs for interventions due to treatment toxicity 
 
PS 2 vs. PS 0/1: 
• Examine the outcome of PS 2 versus PS 0/1 patients with respect to survival, 
toxicity and HRQOL when treated with modern platinum based  
chemotherapy  




4. Patients and Methods 
 
4.1 The VING-study - inclusion criteria 
• Histologically or cytologically confirmed NSCLC 
• Stage IIIB and IV, not eligibly for treatment with curative intention 
• WHO PS 0, 1 or 2, which equals ECOG16 PS 
• No upper age limit 
• No earlier chemotherapy 
• No other active malignancies 
• White blood cells > 3.0, platelets > 100 
• Serum creatinin < 1.5 x upper reference limit 
• Bilirubin, ASAT, ALAT < 2 x upper reference limit 
• Fertile female patients could not be pregnant or breast-feeding and had to use 
contraception 
• Ability to understand written and verbal information 
• Written informed consent   
 
4.2 Baseline investigation 
All patients underwent clinical examination with registration of height and body 
weight, chest X-ray and CT-scan of chest and upper abdomen. Hemoglobin, 
leucocytes, platelets, bilirubin, ASAT, ALAT, γGT, LDH, K, Na, creatinine and 
albumine were measured. The disease was staged according to the clinical stage 





Randomization between VC and GC was done by the Clinical Cancer Research 
Office at the University Hospital of North Norway, either by phone or by fax. Block 
randomization was used and patients were stratified for PS (PS 0/1 vs. PS) and 
clinical stage (III vs. IV).  
 
4.4 Chemotherapy 
In both treatment arms, three courses of chemotherapy were given at three week 
cycles. The chemotherapy was administered as intravenous infusions, mostly on an 
outpatient basis.  
Carboplatin was given as an one hour infusion at day one in each cycle and 
the dose was calculated by the Chatelut formula57 using AUC 4. Gemcitabine or 
vinorelbine was given at days one and eight in each cycle. Gemcitabine at a dose of 
1000 mg/m2 and vinorelbine at a dose of 25 mg/m2 were used.  
For patients aged 75 or older, doses were reduced to 75%. In case of 
hematological toxicity, doses were reduced as described in Table 4: 
 
Table 4. Chemotherapy dose-reduction guidelines. 
White Blood Cells Platelets % dose Vinorelbine             Gemcitabine 
≥ 3.0 ≥ 100 100 100 
2.5 – 2.99 75 - 99 75 75 
< 2.5 < 75 Therapy postponed one week 
 
If treatment was associated with febrile leucopenia or leucopenic infections, 
treatment was delayed until clinical recovery. Later chemotherapy doses were 
reduced by 25%. Treatment was interrupted in case of disease progression, 
unacceptable toxicity or on patients’ request.    
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4.5 Patient follow-up 
Table 5. Trial plan 
 Baseline Chemotherapy  Day 1         Day 8 Follow-up 
Treatment cycle  1 - 3  
Week -1 - 0             0 - 6 9 17 25 33 41 49
Informed consent     X         
Medical history     X         
Physical exam  X  X X X X X X 
Hematology  X X X X X X X X 
Biochemistry     X   X X X X X X 
CT chest/upper abd     X         
Chest X-ray  X  X X X X X X 
QLQ     X   X X X X X X 
 
At the follow-up visit at week 9, a treatment summary was rendered. Investigators 
registered the number of chemotherapy courses, and reported the reasons patients 
did not receive all three courses. These explanations were classified into five 
subgroups:  disease progression, unacceptable toxicity, patients wish, concurrent 
disease or other.  
The lowest values for hemoglobin, white blood cells and platelets during 
treatment were registered and classified according to the WHO toxicity criteria, 
which equals the more frequently used Common Toxicity Criteria version 2.0 by the 
National Cancer Institute79 (Appendix 3). Also, the number of blood transfusions, 
platelet transfusions, leucopenic infections, thrombocytopenic bleedings, admissions 
to hospital due to treatment side-effects and whether the patient received 
granulocyte colony stimulating factor or erythropoietin, were recorded. 
At the follow-up visits every eight weeks from week 17 to 49, performance 
status and body weight were registered. For evaluation of disease progression, CT 
scans were done when indicated as a result of the X-ray findings. If the patient’s 
disease had progressed, the date of progression was given. 
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At the patient’s death, or at week 49, further registrations were done: 
Radiotherapy, surgery or chemotherapy beyond the study medication was 
registered. Date of progression and localization of the first progression or relapse 
were recorded. For patients who died, the cause of death and information on 
whether the patient was examined post-mortem was given.  
Site-visits were performed at hospitals which included ≥ 20 patients. 
Otherwise, missing data were retrieved through phone or mail to the patient’s 
physician.  
 
4.6 Assessment of HRQOL 
The baseline questionnaire was handed to the patient and required completed prior 
to randomization, while the other HRQOL forms were mailed directly to the patients’ 
home address from the randomization office. Questionnaires were completed at 
weeks 0, 3, 6, 9, 17, 25, 33, 41, and 49. This corresponds to each chemotherapy 
course, follow up three weeks post chemotherapy and then accordingly to clinical 
controls every eight weeks until week 49. At lack of response, one reminder was 
mailed after two weeks   
 
4.7 Study endpoints 







4.8 Statistical considerations 
Estimation of study size was based both on survival and HRQOL measures. To 
detect a difference in survival of 11% or HRQOL of 15% between the groups, 
provided a power of 80% and a significance level of 0.05 using two-sided tests, 380 
patients were required. Based on a 5% drop-out, the required patient-number was 
400. 
 For univariate analysis, survival from time of randomization to the date of 
death was compared using Kaplan-Meier estimates and statistical differences were 
estimated by the log-rank test.  Multivariate analyses in paper 2 were carried out 
using the Cox proportional hazards model. Time to progression (TTP) in paper 2 was 
subjected to uni- and multivariate analyses using the same methods. The 
administered amount of chemotherapy, differences in hematological toxicity and 
registered interventions were compared using the chi-square test. The significance 
level was defined at p < 0.05.  
HRQOL items were scored for each patient according to the EORTC scoring 
manual.76 Mean scores, at baseline, during and after chemotherapy, and changes in 
scores from baseline, were compared between the groups in all three papers. Mean 
changes in scores of ≥10 was considered clinically relevant and significant.80 HRQOL 
data are complex of nature and since normal distribution can not be assumed, non-
parametric statistical testing was performed using The Mann Whitney U-test. This test 
was used to compare mean score and mean changes between the groups. 
The area under the curve (AUC) of HRQOL scores plotted against time is a 
summary measure of HRQOL, providing each patient’s longitudinal HRQOL 
experience as a single quantity which then can be compared between groups using t-
tests or one-way ANOVA.81 By using this method, the numbers of comparisons are 
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reduced and the power to detect small but consistent differences that may occur over 
multiple domains of HRQOL is increased.82 There were large differences in baseline 
scores between the PS 2 and the PS 0/1 group. To adjust for these differences, the 
AUC calculation for each patient was based on changes from baseline. Missing data 
were imputed in the AUC analyses. If data from one assessment point were missing, 
the mean value of the two adjacent ones was used. For patients who withdrew or 
dropped out before week 9, the last value carried forward was used to impute the 
missing subsequent values. As this may introduce a bias if the main reason for drop-
out was deterioration, comparisons were performed with data based on the worse 
possible score for the missing data. Standardized AUC (SAUC) was estimated as 
AUC divided by time. SAUC allows for differences in patient survival and corresponds 
to calculating the average HRQOL.81 SAUC from baseline to week 9 in paper 3 was 
compared between PS 0/1 and PS 2 patients using one-way ANOVA.  
In paper 3, patients’ HRQOL responses were classified as improved, stable or 
worse for all HRQOL items at week 9 according to the NCIC CTG standard QOL 
analysis framework.83 Symptom or function items were considered worse if the 
change from baseline was ≥ 10 points towards worse without improvement at any 
time-point. Improvement was defined as ≥ 10 points towards bettering in patients who 
did not deteriorate. Patients, who had less than 10-point changes from baseline at 
the HRQOL assessment or failed to meet the criteria for worsening or improvement, 
were considered stable. Distributions of the categories were tested by χ2.  
Due to multiple comparisons in HRQOL assessments, p-values of < 0.01 were 
considered significant and p < 0.05 indicating a tendency. 
 All analyses were done using the Statistical Package for the Social Sciences, 
SPSS® for windows, versions 12.0, 13.0, 14.0 and 15.0. 
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5. Summary of results 
 
5.1 The patient population 
From September 2003 through December 2004, 33 hospitals (Appendix 4) 
nationwide included 444 patients into the VING study. At the time, this was the 
highest inclusion rate experienced for a Norwegian lung cancer protocol. During the 
inclusion period, approximately 1570 new cases of NSCLC were diagnosed in 
Norway (personal communication, The Norwegian Cancer Registry). Of these, 271 
had local disease, 521 had regional disease and 643 had distant metastasis. For 
132 cases there were no information regarding extent of disease. Assuming that one 
third of the patients with regional disease and one third of those with unknown extent 
of disease were candidates for either surgery or radical radiotherapy,1080 patients 
were candidates for palliative treatment during the period. Hence, approximately 
40% of patients eligible during the inclusion period were included in the VING study. 
This strongly contrasts the US experience where less than 5% of eligible cancer 
patients are included in treatment trials.84 Especially elderly patients are 
underrepresented.85,86  
 The patient flow according to the main randomized study, VC versus GC, is 
presented in Figure 3. The patient flow according to PS is presented in Figure 4.  
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Excluded (n= 12, VC=4, GC=8) 
 
  Not meeting inclusion criteria 
(n= 10) 
  Refused to participate 
(n= 2)
Survival analysis (n= 218). 
Toxicity analysis (n= 216), 2 pts without 
treatment excluded. 
QOL mean score analyses (n=218). QOL 
mean change analyses (n=208), 10 
patients without baseline QLQ excluded.    
Discontinued treatment (n= 36) 
Disease progression n=18 
Treatment toxicity   n=6 
Patients wish           n=1 
Intercurrent disease n=7 
Other reasons          n=4 
Allocated to VC (n= 218) 
Received intervention (n= 216) 
 
Did not receive intervention (n=2): 
acute deterioration of PS 
Discontinued treatment (n= 43) 
Disease progression n=15 
Treatment toxicity    n=6 
Patients wish            n=5 
Intercurrent disease  n=6 
Other reasons           n=11
Allocated to GC (n= 214) 
Received intervention (n= 210) 
 
Did not receive intervention (n= 4): 
acute serious illness (n=3) and  
acute deterioration of PS (n=1) 
Survival analysis (n= 214). 
Toxicity analysis (n=210), 4 pts without 
treatment excluded. 
QOL mean score analyses (n=214). 
QOL mean change analyses (n=210), 5 










Figure 3. Flow of patients through each stage of the VING study. 
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Number of patients included 
N = 432 
Survival analyses: n = 123 
Toxicity analyses: n = 119, 4 pts 
without chemotherapy excluded. 
QOL analyses: n = 118,  
5 pts without baseline QLQ excluded. 
Discontinued treatment n = 40 (33%) 
Disease progression: n = 15 (12 %) 
Treatment toxicity: n = 5 (4 %) 
Patients wish: n = 3 (2%) 
Intercurrent disease: n = 12, (10 %) 
Other reasons: 3 (2 %)  
PS 2  
Allocated to chemotherapy: n = 123 
Received chemotherapy: n = 119 
Did not receive chemotherapy (n= 4): 
Acute deterioration of PS: n=2 
Acute serious illness: n=2 
Discontinued treatment n = 45 (15 %)
Disease progression: n = 19 (6 %) 
Treatment toxicity: n = 7 (2 %) 
Patients wish: n = 3 (1%) 
Intercurrent disease: n = 5, (2%) 
Other reasons: 12, (4 %)
PS 0/1
Allocated to chemotherapy: n = 309 
Received chemotherapy: n =  307 
Did not receive chemotherapy (n=2): 
Acute deterioration of PS: n=1 
Acute serious illness: n=1 
Survival analyses: n = 309 
Toxicity analyses: n = 307, 2 pts 
without chemotherapy excluded. 
QOL analyses: n = 299,  





Performance status (PS) 
Inclusion 
 
Figure 4. Patient flow according to performance status. 
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5.2 Paper 1 
Vinorelbine/carboplatin vs. gemcitabine/carboplatin in advanced NSCLC shows 
similar efficacy but different impact of toxicity 
 
This paper presents the first randomized phase III study comparing vinorelbine and 
gemcitabine in advanced NSCLC. Overall survival, patient assessed HRQOL, toxicity 
and toxicity-related interventions were compared between the two treatment arms. 
Global QOL, nausea/vomiting, dyspnea and pain during the first 17 weeks were pre-
defined as the primary HRQOL items of interest. In total, 432 patients (VC, n=218; 
GC, n=214) defined the study population (Figure 3). Median age in the study 
population was 67 years, 20% were ≥ 75 years old, 61% were male, 71% had stage 
IV disease, 28% had PS 2 and 48% had adenocarcinoma. The study arms were well 
balanced with respect to demographic, clinical and histological characteristics.   
There were no significant survival differences between the two treatment arms 
(p = 0.89). Median survival was 7.3 months in the VC arm and 6.4 months in the GC 
arm. The respective 1-year and 2-year survival rates were 28% vs 30% and 7% vs. 
7%. The four HRQOL items (global QOL, nausea/vomiting, dyspnea, pain) of major 
interest showed no significant differences between the treatment arms, neither at 
baseline nor as change from baseline until week 17. There were more grade 3-4 
anemia (P < 0.01), thrombocytopenia (P < 0.01) and transfusions of blood (P < 0.01) 
or platelets (P < 0.01) in the GC-arm. There was more grade 3-4 leucopenia (P < 
0.01) in the VC-arm, but the rate of neutropenic infections did not differ significantly 
between the arms (P = 0.87).  
In conclusion, the VING-study shows no statistical significant survival 
difference between VC and GC in an unselected patient population mimicking the  
 37
 
everyday clinical setting. HRQOL do not differ significantly between the treatment 
arms, while grade 3-4 toxicity requiring blood and platelet transfusions are less 
frequent in the VC arm when compared to GC in advanced NSCLC.  
 
5.3 Paper 2 
Treatment outcome in performance status 2 advanced NSCLC patients 
administered platinum-based combination chemotherapy 
 
The basis for this second paper was the lack of consensus regarding platinum-based 
combination chemotherapy to PS 2 patients with advanced NSCLC. Using data from 
the VING-study, we evaluated the outcome of PS 2 patients. At inclusion, stratification 
according to PS 2 vs. PS 0/1 was done. The 123 PS 2 patients in the study were 
compared to 309 PS 0/1 patients. Survival, TTP, treatment toxicity, required 
interventions and HRQOL represented by global QOL, nausea/vomiting, dyspnea and 
pain during the first 17 weeks were compared between the two groups of patients.  
The PS groups were well balanced regarding age, gender, disease stage and 
histology at baseline. Among PS 2 patients, 61 were treated with VC and 62 with GC. 
Levels of hemoglobin, LD and albumin differed significantly between the two 
subpopulations (P < 0.01). Mean and median hemoglobin levels were 12.1 and 12.0 
g/dL in PS 2 patients and 13.0 and 13.1 g/dL in PS 0/1 patients. Mean albumin was 
33.3 g/L vs. 37.5 g/L and mean LD 317 U/L vs. 228 U/L in the PS 2 and PS 0/1 
subgroups, respectively. PS 2 patients had lower global QOL and more pain, 
nausea/vomiting and dyspnea at inclusion. They also received less chemotherapy as 
68% received all three chemotherapy courses vs. 85% in the PS 0/1 group (P < 0.01).  
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Median and 1-year survivals were lower in the PS 2 group, 4.5 vs. 8.9 months and 
10 % vs. 37 %, respectively (P < 0.01). The multivariate analysis indicated PS 2             
(P < 0.01, HR 2.09, CI 95% [1.68 – 2.60]) and male gender (P < 0.01, HR 1.30, CI 95% 
[1.07 – 1.60]) to be independent unfavorable prognostic factors for survival. The causes 
of death in PS 2 patients did not differ from the PS 0/1 group (P = 0.81). The majority of 
deaths (87 %) were caused by lung cancer.  
Hematological toxicity did not differ significantly between the groups. The 
frequencies of grade 3 and 4 toxicities as anemia were 16% vs. 12% (p = 0.16), 
leucopoenia 40% vs. 36% (p = 0.22) and thrombocytopenia 22% vs. 24% (p = 0.49) 
in the PS 2 and PS 0/1 group respectively. The mean of the lowest recorded 
individual hemoglobin levels was lower in PS 2 patients (9.3 vs. 9.9 g/100 mL,            
P < 0.01) and these also had more grade 2 anemia (58% vs. 40%, P < 0.01) when 
compared to PS 0/1 patients. PS 2 patients needed more blood transfusions            
(P = 0.03) and were more frequently admitted to hospital (P < 0.01).  
Mean HRQOL item changes from baseline to week 3, 6, 9 and 17 revealed 
clinically meaningful relief of pain and dyspnea in the PS 2 group. There was also a 
tendency towards improved global QOL at week 6. At week 17, 59% of PS 2 patients 
and 47% of PS 0/1 patients had improved or stable PS (P = 0.07).  
In conclusion, the PS 2 patients have shorter survival than PS 0/1 patients. 
Noteworthy, they have acceptable toxicity from platinum-based combination 







Does chemotherapy improve Quality of Life in NSCLC PS 2?  
 
The background for writing the third paper was the fact that 30 - 40% of patients with 
advanced NSCLC are in PS 2, and these patients are strongly underrepresented in 
clinical trials. Data on how the new platinum-based combinations affect their HRQOL 
are scarce and recommended treatment of this important patient group is 
controversial. To explore the treatment impact on HRQOL, SAUC for all HRQOL 
items and HRQOL responses classified as better, stable or worse during the first nine 
weeks were compared between PS 2 and PS 0/1 patients in the  VING-study. 
Whereas the demographic data at baseline were well balanced between the 
groups, HRQOL differed significantly. The PS 2 patients reported lower function for 
global QOL and all the functional scales (p < 0.01). They also had significantly more 
severe symptoms with more fatigue, pain, dyspnea, swallowing problems, cough, 
nausea, insomnia, appetite loss and constipation (p < 0.01).  
The SAUC analyses revealed a tendency towards improved global QOL 
among PS 2 patients when compared to the PS 0/1 group (p = 0.049). For 
symptoms, PS 2 patients achieved significantly more relief of fatigue, dyspnea, and 
sleeping problems (p < 0.01), and they tended towards less pain and appetite loss   
(p < 0.05).  In no items did PS 2 patients experience significant deterioration when 
compared to PS 0/1 patients.  
According to the response analyses, more PS 2 patients achieved 
improvement in global QOL and cognitive function (p < 0.01) and they tended 
towards more improvement of role function (p = 0.01). They also experienced more 
relief of dyspnea measured by QLQ-C30 (p < 0.01), and tended to more 
 40
improvement of fatigue, swallowing problems and appetite loss (p < 0.05) when 
compared to PS 0/1 patients.  
In conclusion, the PS 2 NSCLC patients had valuable HRQOL benefits from 
platinum-based combination therapy, with a more profound improvement of global 




6.1 Paper 1 
Platinum in combination with a third-generation drug (gemcitabine, vinorelbine, 
docetaxel or paclitaxel) has been established as standard first-line treatment of 
advanced NSCLC. The best combination among these platinum doublets still, 
however, remains an open question. We showed that the VC regimen already 
established in Norway at the time, is an adequate treatment alternative and even 
favorable with respect to hematological toxicity when compared to GC.  
A meta-analysis including 4556 patients from 13 randomized trials, found 
gemcitabine-platinum doublets slightly superior to the non-gemcitabine combinations 
regarding progression-free survival.87 When limiting the analyses to the other novel 
platinum-based doublets, the difference was no longer significant (HR 0.93, CI 0.86–
1.01). An expert opinion on GC combination therapy in advanced NSCLC found GC 
to be among the better tolerated available first-line regimens in this setting, although 
myelotoxicity can be significant.88 The opinion was based on an evaluation of 
pharmacology, preclinical and clinical data, and the aim was to support the use of this 
regimen. No trials including vinorelbine were referred to.  
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The median survival in our study was somewhat lower when compared to 
other phase III trials. This can be explained by the large proportion of PS 2 patients 
















PS 0: 1-y surv. 54%, median surv. 12.6 mths
PS 1: 1-y surv. 30%, median surv. 7.6 mths





Figure 5.  Overall survival according to performance status. 
 
As Figure 5 demonstrates, survival data in advanced NSCLC patients is highly 
dependent on the patients’ PS. In this perspective, thorough analyses of possible 
reasons for survival differences of a few weeks, is of no interest unless the study 
populations are similar regarding PS. When PS 2 patients were excluded from our 
analysis, the median survival increased from 7.3 to 9.0 in the VC and from 6.4 to 8.9 
months in the GC arm.  
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The higher rate of leucopenia experienced in the VC arm (45% vs. 30%) did 
not result in higher infection rates and was mainly laboratory toxicity without direct 
impact on patients’ lives. On the other hand, the markedly higher incidence of grade 
3-4 anemia (19% vs. 6%) and thrombocytopenia (44% vs. 3%) in the GC arm, led to 
additional symptoms and significantly more frequent transfusions of blood products, 
requiring hospitalization and further costs. In general, our toxicity data are consistent 
with previous studies29,51 and support the chosen chemotherapy doses.  
An overall compliance of 88% for completing HRQOL forms during the study 
period is considered good. The present HRQOL analyses did not reveal any 
significant differences between the two treatment regimens. The timing of the 
HRQOL questionnaires was probably not ideal to unmask possible differences in 
acute chemotherapy-related toxicity between the treatment arms as the patients were 
asked to complete these forms just prior to chemotherapy. Completing the 
questionnaires a few days after chemotherapy may have been a better approach. 
 
6.2 Paper 2 
This comparison of PS 0/1 and PS 2 patients indicates that despite a modest 
survival, carboplatin-based combination chemotherapy is tolerated in PS 2 patients 
and improves these patients’ HRQOL.  
Combination chemotherapy to advanced NSCLC PS 2 patients is 
controversial, as accounted for in the background of this thesis. The ASCO 
Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 200327 
stated that single-agent chemotherapy would be sufficient for PS 2 patients. This was 
based on the fact that non-platinum based doublets were suggested equivalent to 
platinum doublets in terms of efficacy, but with less nonhematologic toxicity.89 Still, 
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non-platinum combinations were described to yield higher toxicity than single-agent 
chemotherapy and may for that reason not be appropriate for patients with poor 
performance status. By 2003, no randomized trials comparing combination 
chemotherapy with single-agent chemotherapy in PS 2 NSCLC patients had been 
published. On the other hand, subgroup analyses from randomized trials suggested 
that PS 2 patients had a significantly higher rate of toxicity than PS 0/1 patients. This 
was based on four randomized trials.35,37-39 In the ECOG trial 1594,37 four platinum-
based chemotherapy regimens for advanced NSCLC were compared without 
superiority for any of these. After accrual of 68 PS 2 patients, a high incidence of 
adverse events including five deaths led to an early terminated inclusion of PS 2 
patients. The authors advised against the routine use of platinum-based 
chemotherapy to patients with a poor performance status. In a subsequent subgroup 
analysis of the outcome of these 68 PS 2 patients, underlying disease and not the 
treatment toxicity, was found to be responsible for their poor outcome.39 Still, the 
advice against platinum-based combination chemotherapy to NSCLC PS 2 patients 
was maintained by the authors.  
In contrast to this view, Lilenbaum et al40 compared the efficacy of combination 
chemotherapy vs. single-agent therapy in advanced NSCLC and observed better 
survival rates in PS 2 patients treated with combination chemotherapy than those 
treated with single-agent therapy (p = 0.02). Later, a randomized phase II trial, 
evaluating two dose-attenuated platinum-based doublets in advanced NSCLC PS 2 
patients,90 concluded that the combination chemotherapy was feasible with 
acceptable toxicity despite inferior survival compared to PS 0/1 patients. 
The lack of differences in hematological grade 3 and 4 toxicity between the PS 
subgroups is in agreement with previous publications 39,40,91,92. Still, more PS 2 
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patients received blood transfusions, which probably reflect the lower hemoglobin 
level already at baseline. More frequent admissions to hospitals among the PS 2 
patients might be explained by anemia and symptoms due to more advanced 
disease.  
The present report reveals that despite a shorter survival, PS 2 patients have 
acceptable toxicity, achieve better improvement of pain and dyspnea and tend 
towards a better global QOL when compared to PS0/1 patients. Improvements in PS 2 
patients’ HRQOL is supported by a study published in 200135 and in a more recent 
phase II study.93 Also, clinical improvement, defined as achieving a good PS during 
combination chemotherapy, has been reported in advanced NSCLC patients with poor 
PS.94 
 
6.3 Paper 3 
In this paper, HRQOL of advanced NSCLC PS 2 patients is explored in detail. To our 
knowledge, this is the first detailed HRQOL study in advanced NSCLC PS 2 patients 
administered platinum-based combination chemotherapy. The PS 2 patients had 
more improvement of global QOL, cognitive function, fatigue, pain, dyspnea, sleeping 
problems and appetite loss than PS 0/1 patients.   
HRQOL data in NSCLC PS 2 patients are highly demanded in the literature. A 
European experts panel argued for HRQOL assessments in evaluating symptom 
relief and clinical benefit as endpoints in trials including NSCLC PS 2 patients.65     
An in press review on treatment of NSCLC PS 2 patients concludes that 
chemotherapy appears justified and that the emphasis for these patients’ care should 
be on maintenance and improvement of QOL.95  Also, the National Institute of 
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Clinical Excellence19 describes the need for further research in HRQOL aspects 
regarding NSCLC PS 2 patients treated with chemotherapy. 
HRQOL benefits among NSCLC PS 2 patients have been reported previously. 
In a subgroup analysis based on two randomized parallel trials of mitomycin, 
ifosfamide and cisplatin96, the most significant HRQOL improvements during 
chemotherapy was observed in the PS 2 rather than the PS 0/1 group.35 
Furthermore, in a recent randomized phase II trial of first line erlotinib monotherapy 
versus the combination of carboplatin and paclitaxel in advanced NSCLC PS 2  
patients,93 HRQOL tended to improve rather than worsen in both treatment arms. 
The authors concluded that unselected advanced NSCLC PS 2 patients are best 
treated with combination chemotherapy in first-line.   
In a recently published phase III study, up to six cycles of single-agent 
paclitaxel poliglumex was compared with single-agent gemcitabine or vinorelbine in 
chemotherapy-naïve advanced NSCLC PS 2 patients.97 A total of 477 patients were 
included between Dec 2002 and June 2004, which according to the authors make 
this the largest series of NSCLC PS 2 patients in a clinical trial. The primary endpoint 
was overall survival, followed by efficacy measures and tolerability. The authors 
concluded that survival rates between the arms were comparable, and patients in the 
experimental arm (paclitaxel poliglumex) had less toxicity. HRQOL was assessed by 
the FACT-LCS questionnaire and compared between the arms at baseline and week 
three without significant differences. Based on information in the article, the HRQOL 
compliance rate was 70%. In this poor PS patient group, HRQOL results were 
presented using less than 4 lines, and were not discussed in the article. This paper 
demonstrates the difficulties in getting through advocating the importance of HRQOL 
analyses in the palliative treatment of NSCLC.  
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 Analyzing HRQOL data is challenging and so is presentation of such data in a 
way that make them comprehensible and useful to clinicians without particular 
training in interpretation of these kinds of results. HRQOL data are complex of nature 
with several measures at different time points for each patient. Often, the aim is to 
describe HRQOL over time, which demands summarized measures for each patient 
and subsequent comparisons between the groups.81  As emphasized in the paper, 
analyses of unplanned sub-group comparisons should be interpreted with 
caution.98,99 On the other hand, significant findings give rise to new hypotheses and 
thus initiate important research. The presented subgroup analyses revealed clinically 
meaningful improvements of symptoms and functions in advanced NSCLC PS 2 
patients treated with platinum-based combination chemotherapy. 
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7. Conclusions and implications for further research 
In conclusion, the comparison of VC and GC revealed no significant differences in 
survival or HRQOL, while clinically relevant toxicity was more frequent in the GC arm. 
These results supported VC as our standard first line treatment for advanced 
NSCLC. For subsequent randomized studies initiated by the Norwegian Lung Cancer 
Study Group, VC has been included as the standard arm. Nevertheless, the GC 
combination is widely accepted as a valuable treatment option for these patients as 
well. Future research will probably, to a larger extent, focus on new targeted 
therapies instead of further exploration of traditional chemotherapy combinations.    
Clinical valuable HRQOL benefits from combination chemotherapy were seen 
among PS 2 patients. This reflects their heavier symptom and disease burden, and 
the greater potential for treatment effect on symptoms in this group. It will be 
important to generate more research in this area; hence inclusion of NSCLC PS 2 
patients into randomized trials should be encouraged in order to increase our 
knowledge within this field. 
 Advanced lung cancer patients in general, and those with PS 2 in particular, 
suffer from severe symptoms during progression of their disease. There should be a 
strong focus on these patients’ HRQOL and future research on their optimal palliative 
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Page 20, ref. 41. 
..”individual data from 2666 patients revealed an increased 1-year survival in PS 2 
patients from 5% after obsolete chemotherapy to 11% after novel therapy.41” should 
read: …”individual data from 2714 patients revealed an increased 1-year survival in 
patients with PS ≥ 2 from 8% to 14%.41” 
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